14 MS Experimental Therapies You Should Know About
1. ALKS 8700
Alkremes Inc. is developing a novel formulation called ALKS 8700 to treat demyelinating neurodegenerative disorders of the central nervous system such as multiple sclerosis (MS).
Ankar Pharmaceuticals, a Spanish-Filipino start-up in biopharmaceuticals, has been working on the development of their premier drug candidate for treating multiple sclerosis (MS), called AP-1. The unique property of this pipeline drug is its ability to excel in terms of prophylactic measures in people suspected to be affected by the condition, as well as in those with a full-blown case history of MS and relapses. This gives the oral formulation an advantageous edge over many contemporary drugs, fingolimod being the latest to be approved, for treating MS.
APD334 is Arena Pharmaceuticals’ latest novel therapeutic remedy to treat autoimmune diseases like multiple sclerosis (MS), psoriasis and rheumatoid arthritis. The drug is an oral formulation, which is also an agonist (a substance which exerts its effect after binding to a particular receptor) of the S1P1 receptor. This receptor is involved in the regulation of immune responses in the body and hence is a potent target to treat autoimmune disorders.
Antisense Therapeutics is currently developing ATL1102, a novel therapeutic candidate for treating relapsing and remitting forms of multiple sclerosis (MS). ATL1102 is an antisense inhibitor of the CD49d subunit of the VLA-4 (Very Late Antigen-4) receptor on the surface of lymphocytes. The concept of making antisense drugs (therapies containing the non-coding part of a messenger RNA molecule, which is a key component of DNA replication and protein synthesis, to end the process of protein synthesis of that particular gene which is the causative agent of a particular condition) has been used over the years to treat different types of cancers, amyotropic lateral sclerosis, diabetes and diseases like asthma and arthritis, with an inflammatory component.
California-based pharmaceutical company Bionure is currently developing a novel neuroprotective and remyelinating therapy called BN201 for acute optic neuritis (AON), glaucoma (GL) and multiple sclerosis (MS).
CTP-354 is Concert Pharmaceuticals’ novel, potentially first-in-class, non-sedating, once-daily oral formulation aimed at treating conditions like cerebral palsy, multiple sclerosis (MS), amyotropic lateral sclerosis (ALS), spinal cord injury and hereditary paraplegia, all of which contribute to spasticity in humans. As part of developing CTP-354, Concert is utilizing the deuterated chemical entity DCE platform, which involves the addition and modification of existing, approved drugs or those studied clinically beforehand with deuterium to improve safety and clinical efficacy.
GLX1112 is a novel formulation being developed by the San Francisco Bay-based Glialogix, Inc., aimed at treating progressive forms of multiple sclerosis (MS) in patients. A unique feature about this therapy is that it is a reformulation of an existing FDA approved drug that has been used for more than 50 years for treating non-neurological conditions at a higher and more chronic dosage, which has poor bioavailability, limiting its entry into the blood-brain barrier and is associated with gastrointestinal toxicity among other common side-effects.
8. Ibudilast (MN-166)
Ibudilast is a formulation labeled as MN-166 by MediciNova. It is currently considered a “phase II staged, first-in-class, orally bioavailable, small molecule,” which has immunoprotective, neuroprotective, bronchodilatory and vasodilatory properties, and can be used effectively in treating drug addiction, asthma, and progressive neurodegenerative disorders, including multiple sclerosis (MS).
MS is a neurodegenerative condition where the body’s immune system attacks the nerve fibers and protective myelin sheaths covering them. The disease affects around 2.5 million people worldwide, and 400,000 people in the US alone. MS leads to destruction of nerve fibers and loss of muscle control, as well as other serious, progressive damage to the central nervous system (CNS). Relapsing-remitting multiple sclerosis (RRMS) is the most common form of the disease, and secondary progressive multiple sclerosis (SPMS) is the most common consequence of RRMS.
Atlanta-based Inhibikase Therapeutics’ Inc. is currently developing the novel formulation ikT-001Pro for treating progressive multifocal leukoencephalopathy (PML), one of the major complications of multiple sclerosis (MS) treatments caused by the use of immunosuppressants and immunomodulators, which hamper the body’s ability to combat infectious pathogens. The John Cunningham Virus (JCV) is the causative agent of PML and affects the white matter of the brain, destroying motor neurons and impairing cognitive ability.
Cases of PML have been reported mostly when Natalizumab has been used to treat relapsing and remitting forms of MS, either via monotherapy or in combination with Interferon beta – 1a. Patients with an earlier JCV infection with viral antibodies still existing in body fluids have a reactivation of the virus during immunosuppression which causes PML.
Australia and New Zealand based Innate Immunotherapeutics Limited has been working on the clinical development of their premier drug candidate called MIS416 aimed at treating patients with secondary progressive multiple sclerosis (MS). The therapy is an intravenous formulation consisting of an immunomodulatory micro particle which targets both regulatory and defensive functions of the innate immune system, with a novel target, the myeloid cells (a subset of innate immune cells), which has not been targeted by any therapy currently marketed, or in trials.
Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche, whose focus is manufacturing novel drugs to treat neurodegenerative diseases with unmet medical needs, such as multiple sclerosis. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS). Ocrelizumab is not yet an approved therapy — it is still be tested in clinical trials — but the therapy has shown promising results in treating primary progressive multiple sclerosis (PPMS).
RHB-104 is RedHill Biopharma’s drug candidate aimed at treating several inflammatory conditions such as Crohn’s disease, rheumatoid arthritis, and multiple sclerosis (particularly the relapsing-remitting form, RRMS). The drug is an oral capsule with potent intracellular, antimycobacterial, neuroprotective, and anti-inflammatory properties, according to Redhill.
Tcelna, formerly known as Tovaxin, developed by Texas based Opexa Therapeutics (previously known as PharmaFrontiers) is a novel approach to tailoring an individual’s immune response to myelin in patients with secondary progressive multiple sclerosis (SPMS). It is an autologous T-cell vaccine containing autoreactive T cells. Such a concept is comparatively new in the pharmaceutical industry and as a result, the US Food and Drug Administration has granted fast-track status to the therapy in terms of clinical development and subsequent manufacturing and commercialization, in aid of patients and fulfillment of the major unmet medical needs currently facing the treatment of SPMS.
14. Zenapax (Daclizumab)
Daclizumab, manufactured under the trade name Zenapax, is a humanized monoclonal antibody that has been used in treating extreme immune responses in transplant patients and is currently an investigational drug for the treatment of patients with multiple sclerosis (MS).
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.